Navigation Links
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
Date:4/23/2009

n, treatment or cure of any disease or illness. It may not be sold or promoted in the United States unless and until approved for marketing by the FDA. Similar restrictions apply in other countries.

About Study 204

In the Phase IIb study (previously disclosed as Study 204), 278 treatment naive, genotype 1 patients were randomized with the following patient demographics: mean age 48.8 yrs, 61.1% male, 30% African-American or Latino, 80.7% viral load ¿400,000 IU/mL and 82.1 kg mean weight. Week (TW) 60 efficacy and safety results for the intention-to-treat (ITT) population are shown in the table above.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including, but not limited to, statements regarding the potential for taribavirin in the treatment of hepatitis C, and the continuing role of ribavirin or taribavirin in the treatment of hepatitis C, that are based on management's current expectations and involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to the clinical development of new products, regulatory approval processes, that results from week 60 in the phase IIb clinical trial are not necessarily predictive of the entire phase IIb trial or a phase III trial, and other risks as set forth under the caption Risk Factors in the company's most recent annual or quarterly report filed with the SEC, which factors are incorporated h
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
2. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
3. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
6. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
7. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
8. Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
9. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
10. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
11. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Asians living in Canada have a higher rate of ... with while people, McMaster researchers have found. , ... Medical Association Journal (CMAJ Open) and may be ... fastest-growing ethnic groups in the country is the more ... comprising about three percent of the population. They include ...
(Date:9/22/2014)... researchers have published a pilot study showing the ... people with multiple sclerosis (MS). Improvements were ... and pain. "Development and effectiveness of a ... Description and outcomes" was epublished ahead of print ... of MS Care (doi: 10.7224/1537-2073.2013-045). The authors ...
(Date:9/22/2014)... -- Two new prescription devices approved by the U.S. ... for people with migraine headaches who don,t tolerate migraine ... device -- the Cefaly -- is designed to prevent ... is meant to be used when migraines first start, ... been looking for alternative migraine treatments. Because these devices ...
(Date:9/22/2014)... Severe weather can occur with little warning, so it’s ... of National Preparedness Month, Amica Insurance is offering the ... unexpected:, , Build an emergency supply kit. It ... gallon of water per person per day for at least 72 ... includes pets so your family knows what to do and where ...
(Date:9/22/2014)... September 22, 2014 The New York ... of Surgery at the Icahn School of Medicine at ... York Group for Plastic Surgery gives residents of New ... a team of world-renowned plastic surgeons performing innovative reconstructive ... Salzberg, MD, who led NYGPS, was named the Director ...
Breaking Medicine News(10 mins):Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3
... San Diego, CA, August 18, 2009 While video gaming ... adults, research shows that the average age of players in ... Disease Control and Prevention (CDC), Emory University and Andrews University ... from 19 to 90 in the Seattle-Tacoma area on health ...
... INDIANAPOLIS, Aug. 17 Eli Lilly and Company (NYSE: ... for the Eastern District of Michigan has granted a motion by ... ,826 patent, or method-of-use patent, for Gemzar((R)) (gemcitabine HCl for injection) ... no bearing on Gemzar,s compound patent, which remains valid until November ...
... , , MIAMI, Aug. 17 In the ... Make You Thin , writer John Cloud tells us that these days, the ... wasting their time. He says that "exercise, in other words, isn,t necessarily helping ... After reading this article, Marta Montenegro is on a ...
... , WASHINGTON, Aug. 17 Earlier this ... Abbey College, a Roman-Catholic institution, must provide insurance coverage for ... http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ) , , The ruling goes ... state law which provides for exemption to for religious entities. ...
... A new study shows that elderly patients who ... ulcer bleeding had a two-day shorter hospital stay and ... patients who did not receive endoscopy within the first ... Center in Cleveland, Ohio, note that unless specific contraindications ...
... benign, others might pose dangers, experts say , MONDAY, ... skin can "trap" large amounts of indoor ozone, then "spit" ... the skin and the lungs, new research suggests. , "They ... ozone and cause more irritation to the skin," explained one ...
Cached Medicine News:Health News:New study finds links between video-game playing and health risks in adults 2Health News:New study finds links between video-game playing and health risks in adults 3Health News:U.S. District Court Rules Against Lilly Regarding Gemzar Patent 2Health News:U.S. District Court Rules Against Lilly Regarding Gemzar Patent 3Health News:U.S. District Court Rules Against Lilly Regarding Gemzar Patent 4Health News:Editor-In-Chief of SOBeFiT Magazine, Marta Montenegro, Says Time Magazine's Article 'Why Exercise Won't Make You Thin' Sends the Wrong Message 2Health News:Editor-In-Chief of SOBeFiT Magazine, Marta Montenegro, Says Time Magazine's Article 'Why Exercise Won't Make You Thin' Sends the Wrong Message 3Health News:Editor-In-Chief of SOBeFiT Magazine, Marta Montenegro, Says Time Magazine's Article 'Why Exercise Won't Make You Thin' Sends the Wrong Message 4Health News:Family Research Council President Tony Perkins Asks: Is This What President Obama Means by 'Robust' Conscience Protections? 2Health News:Endoscopy within 24 hours shows better outcomes in elderly with peptic ulcer bleeding 2Health News:Endoscopy within 24 hours shows better outcomes in elderly with peptic ulcer bleeding 3Health News:Endoscopy within 24 hours shows better outcomes in elderly with peptic ulcer bleeding 4Health News:Toxins May Form When Skin, Indoor Ozone Meet 2Health News:Toxins May Form When Skin, Indoor Ozone Meet 3
(Date:9/22/2014)... , Sept. 22, 2014  For many ... surgery often means facing the prospect of large, ... be imagined, regular activities are also impacted, such ... the severity of the problem, some patients even ... which can even lead to permanent damage for ...
(Date:9/22/2014)... SAN FRANCISCO , Sept. 22, 2014  Sutro ... FierceBiotech as one of 2014,s Fierce 15 ... promising private biotechnology companies in the industry.  ... A-list group of backers as well as industry partners ... developing antibody-drug conjugates and bispecifics," says John Carroll ...
(Date:9/22/2014)... Sept. 22, 2014  Seres Health, a clinical-stage therapeutics ... human microbiome, today announced that it has been named ... 15 biotechnology companies, designating it as one of the ... "Amid a great deal of ain,t-it-cool science ... and commitment to practical therapeutic development," says Damian ...
Breaking Medicine Technology:Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3Seres Health Named a "Fierce 15" Biotech Company for 2014 2
... Six-Month Data Show Bifeprunox Maintained Stability,Significantly Longer ... and,Lipid Profile Comparable with Placebo , MARIETTA, ... - Solvay,Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division ... study results on,bifeprunox, an investigational treatment for ...
... Support FDA Approval of SEROQUEL XR--, WILMINGTON, ... announced that two analyses from a large-scale,study ... (quetiapine,fumarate) Extended-Release Tablets, a once-daily medicine for ... presented today,at the annual meeting of the ...
Cached Medicine Technology:New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 2New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 3New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 5New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 6New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 7New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 8New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 9
Mounted on an extremely lightweight,and flexible cotton headband, the,Trueview Sport adjusts around the head,and the crown strap for a comfortable,and secure fit,...
The Convertible lets you attach the,High Lite optic directly to your loupes....
Mounted on a remarkably lightweight and,flexible cotton headband with crown strap,the Sport is fully adjustable....
... content (93% by volume) of any DBM ... handling characteristics, which will enhance any graft ... or as a graft extender for larger ... high molecular weight biocompatible carrier allows DBX ...
Medicine Products: